rEV 131

Drug Profile

rEV 131

Alternative Names: EV-131; rEV-131

Latest Information Update: 09 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evolutec
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Recombinant proteins
  • Mechanism of Action Histamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Allergic conjunctivitis; Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease; Postoperative inflammation

Most Recent Events

  • 04 Dec 2006 A phase IIb trial of rEV 131 in Allergic rhinitis did not meet its primary endpoint
  • 22 Jun 2006 Phase-II clinical trials in Postoperative inflammation in USA (Ophthalmic)
  • 16 Jun 2006 Phase-II clinical trials in Allergic rhinitis in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top